DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for young brain cancer patients in groundbreaking trial
Disease control Not yet recruitingThis study is testing whether adding a new drug called ADI-PEG 20 to standard radiation and chemotherapy can help control aggressive brain tumors in children, teens, and young adults. The first part will find the safest dose, and the second part will see if the combination helps …
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1, PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Nose spray trial offers hope for kids with devastating brain tumors
Disease control Not yet recruitingThis early-stage study is testing the safety of an experimental nose spray called NEO100 in children and teenagers with aggressive brain tumors. The main goal is to find a safe dose and see if the medicine can successfully reach the tumor in the brain. Researchers will also check…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Mar 18, 2026 18:25 UTC